姜黄素联合坦索罗辛和非那雄胺治疗良性前列腺增生症男性患者：一项单中心随机对照研究。
Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: a single center, randomized control study.
作者信息
Qiao Jing, Gan Yu, Gong Yuchen, Song Qingtian, Zhang Bo, Li Bingsheng, Ru Feng, Li Yang, He Yao
机构信息
Department of Ophthalmology, Hunan Children's Hospital, Changsha, China.
Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
出版信息
Transl Androl Urol. 2021 Aug;10(8):3432-3439. doi: 10.21037/tau-21-567.
BACKGROUND
To perform a prospective, randomized, single center study to investigate the efficacy of combined use of curcumin, an anti-inflammatory agent, with the best standard management (BSM, tamsulosin and finasteride) in benign prostatic hyperplasia (BPH) patients.
METHODS
One hundred and twenty-two consecutive patients were randomized to receive tamsulosin 0.2 mg, finasteride 5 mg, and curcumin 2,250 mg once a day (curcumin + BSM group, n=61) versus tamsulosin 0.2 mg, finasteride 5 mg, and placebo (BSM group, n=61) for 6 months. The safety of treatments and their efficacy on improving waist circumference (WC), periprostatic fat thickness (PPFT), lower urinary tract symptoms (LUTS), and sexual function were assessed at baseline and month 6.
RESULTS
One hundred and sixteen patients completed the whole procedure (116/122, 95.1%). There were significant improvements in prostate volume (PV), maximum flow rate (Qmax), the International Prostate Symptom Score (IPSS), IPSS-voiding subscore (IPSS-V), IPSS-storage subscore (IPSS-S), and quality of life (QoL) from baseline after treatment in both groups. Additionally, both WC and PPFT decreased significantly after treatments than those at baseline in the curcumin + BSM group. Also, WC and PPFT in the curcumin + BSM group were significantly lower than those in the BSM group. In addition, IPSS-S, QoL score, and the 5-item version of the International Index of Erectile Function (IIEF-5) in the curcumin + BSM group improved significantly compared with those in the BSM group.
CONCLUSIONS
We conclude that curcumin combined with tamsulosin and finasteride has more beneficial effects in reducing PPFT, protecting erectile function, improving urinary retention symptoms, and QoL scores in BPH patients compared to tamsulosin and finasteride alone.
TRIAL REGISTRATION
Chinese Clinical Trial Registry ChiCTR2100043800.
背景
进行一项前瞻性、随机、单中心研究，以调查抗炎药姜黄素与最佳标准治疗（BSM，坦索罗辛和非那雄胺）联合使用对良性前列腺增生（BPH）患者的疗效。
方法
122例连续患者被随机分为两组，一组每天接受一次坦索罗辛0.2mg、非那雄胺5mg和姜黄素2250mg（姜黄素+BSM组，n = 61），另一组接受坦索罗辛0.2mg、非那雄胺5mg和安慰剂（BSM组，n = 61），为期6个月。在基线和第6个月时评估治疗的安全性及其对改善腰围（WC）、前列腺周围脂肪厚度（PPFT）、下尿路症状（LUTS）和性功能的疗效。
结果
116例患者完成了整个过程（116/122，95.1%）。两组治疗后前列腺体积（PV）、最大尿流率（Qmax）、国际前列腺症状评分（IPSS）、IPSS排尿子评分（IPSS-V）、IPSS储尿子评分（IPSS-S）和生活质量（QoL）较基线均有显著改善。此外，姜黄素+BSM组治疗后WC和PPFT均较基线显著降低。而且，姜黄素+BSM组的WC和PPFT显著低于BSM组。此外，与BSM组相比，姜黄素+BSM组的IPSS-S、QoL评分和国际勃起功能指数5项版（IIEF-5）有显著改善。
结论
我们得出结论，与单独使用坦索罗辛和非那雄胺相比，姜黄素联合坦索罗辛和非那雄胺在降低BPH患者的PPFT、保护勃起功能、改善尿潴留症状和QoL评分方面具有更有益的效果。
试验注册
中国临床试验注册中心ChiCTR2100043800
Zotero 插件